JZ is the mandatory claim-line attestation that zero drug was discarded from a single-dose container. It goes on the administered line — never on a separate line, never paired with JW — whenever the dose drawn equals the total billing units of the single-dose vial(s) opened. Since July 1, 2023, every Medicare Part B single-dose container claim must carry either JW (waste) or JZ (no waste). A line that carries neither rejects; a line that carries both rejects as mutually exclusive.
JZ was introduced by CMS Transmittal R11603CP / Change Request 12056 ("Discarded Drug and Biological Refund Implementation; Modifier JZ") and became required on Medicare Part B claims effective July 1, 2023. Edit-cycle enforcement — meaning hard rejections from the MAC, not just informational warnings — took effect October 1, 2023. JZ is governed by the same authority as JW: CMS Internet-Only Manual Publication 100-04, Chapter 17, §40 (Discarded Drugs and Biologicals).
The statutory hook is Section 90004 of the Infrastructure Investment and Jobs Act of 2021, which directs CMS to recover refunds from manufacturers for unused single-dose-container drug above a threshold. JW captures the wasted units. JZ closes the data gap: by requiring a positive attestation on every no-waste claim, CMS can distinguish a true zero-waste administration from a claim where the biller simply forgot to add JW. Without JZ, the quarterly refund calculations would be biased upward (every missing-modifier claim would look like a no-waste claim by default).
JZ is the dominant scenario for fixed-dose biologics whose standard adult dose matches a whole-vial multiple. Keytruda 200 mg flat (two 100 mg vials), Tysabri 300 mg flat (one 300 mg vial), Yervoy 200 mg flat in certain regimens (one 200 mg vial), and most fixed-dose immunoglobulin and biosimilar regimens generate JZ on nearly every administration. For these drugs, the biller's default expectation should be JZ; a JW claim is the exception, not the rule.
The largest audit risk on JZ is using it as a coding shortcut to avoid the work of computing and reporting JW on partial-vial scenarios. UnitedHealthcare and Medicare contractor audits compare per-NPI JZ frequency against expected waste patterns by drug; an oncology practice billing 100% JZ on weight-based Abraxane or Avastin will draw a documentation request.
Medicare Part B mandates JZ or JW on every single-dose container line from October 1, 2023 forward. Commercial payers have largely aligned to the CMS convention, though enforcement strictness varies. UnitedHealthcare audits most aggressively for JZ misuse on weight-based dosing; the other commercials warn-and-pass more often.
| Payer | JZ required when no waste? | Notes |
|---|---|---|
| Medicare (Part B) | Yes — rejects without JW or JZ | Source-of-truth payer. Edit cycle enforces both modifiers since 10/1/2023. MACs reiterate the IOM Ch.17 §40 rule verbatim in their local articles. |
| UnitedHealthcare | Yes | Aligns with CMS at adjudication. Post-payment audit overlay flags JZ on weight-based or BSA-based dosing for drugs where physiology rarely lands on a whole-vial multiple. If JW is absent from a weight-based dose claim and JZ is present, the claim is audit-eligible. |
| Aetna (CVS Health) | Yes | Aligns with CMS. Aetna oncology medical-policy bulletins reference IOM Ch.17 §40 directly. CVS Specialty pre-filled syringes do not generate JZ. |
| Cigna / Express Scripts | Yes | Aligns with CMS. Accredo dispensing reports surface the waste/no-waste calculation; the practice still appends JZ on the buy-and-bill medical claim where applicable. |
| Humana | Yes | MA-heavy book follows CMS by default. CenterWell Specialty pre-mixed product does not generate JZ. Humana commercial PPO mirrors the Medicare alignment. |
| Denial pattern | What it means | Fix / appeal language |
|---|---|---|
| JZ omitted on single-dose vial (CARC 16 / RARC N822) | Single-dose container claim shows the administered amount exactly matching vial size(s) but neither JW nor JZ is on the line. Medicare reads this as a missing required modifier and rejects. | Resubmit with JZ appended to the administered line. Appeal language: “Per CMS Transmittal R11603CP and IOM Pub 100-04, Chapter 17, §40, the corrected claim appends modifier JZ to the [J-code] administered line, attesting that zero drug was discarded from the single-dose container(s) used. Administered units = [N] = total billing units of the [M] single-dose vials opened.” |
| JZ + JW on same line (mutually exclusive) | Both modifiers appended to one line. JZ and JW describe opposite scenarios (no discard vs discard) and cannot coexist on a single line. | Resubmit with the correct single modifier. If no waste, retain JZ and remove JW. If waste occurred, restructure as two lines: administered (no modifier) plus discarded (JW). Appeal language: “CMS Transmittal R11603CP defines JW and JZ as mutually exclusive. The corrected claim removes the inappropriate modifier and structures the line(s) per IOM Pub 100-04, Chapter 17, §40.” |
| JZ on multi-dose vial | JZ appended to a line for a drug supplied in a container labeled “Multi-Dose” or “MDV.” Multi-dose vials are outside the scope of the JW/JZ rule regardless of dose-to-vial math. | Resubmit without JZ (and without JW). Appeal language: “Per CMS IOM Pub 100-04, Chapter 17, §40, JZ applies only to single-dose containers as defined by FDA labeling. The product administered is supplied in a multi-dose vial (NDC [X], FDA label designation: Multi-Dose), so no waste-or-no-waste modifier is required.” Attach the FDA package insert page showing the MDV designation. |
| JZ on biosimilar with reference-product J-code | JZ correctly reflects no waste but the base HCPCS reports the reference biologic (e.g., J2778 for Lucentis) rather than the biosimilar actually administered (e.g., Q5124 for Cimerli). The modifier is right; the base code is wrong. | Resubmit with the biosimilar HCPCS on the administered line, JZ retained. Appeal language: “The product administered was [biosimilar name], NDC [X], reportable under HCPCS [Q-code]. JZ reporting rules per IOM Pub 100-04, Chapter 17, §40 apply identically to biosimilars; the corrected claim uses the biosimilar HCPCS on the administered line with JZ attesting to zero discarded drug.” |
| JZ on a claim where chart shows waste | Post-payment audit identifies a JZ-attested claim where the medical record documents leftover drug. This is a coding integrity failure with recoupment exposure and, in aggregate patterns, potential False Claims Act risk. | Voluntarily refund and recode as a JW two-line construction. Appeal language is not the right tool here — the right tool is correction, repayment, and an internal-controls review. Audit risk language: “Self-disclosure under [payer]'s overpayment policy, with corrected claim reflecting the administered units and a separate JW line for the [Y] discarded units per IOM Pub 100-04, Chapter 17, §40.” |
JZ attests that zero drug was discarded from a single-dose container. JW reports the units of drug that were discarded when leftover did occur. The two are mutually exclusive on a single claim line, and every single-dose container line must carry exactly one of them — never both, never neither.
Effective July 1, 2023, per CMS Transmittal R11603CP and Change Request 12056, JZ is required on every Medicare Part B single-dose container claim line where no drug was discarded. Edit-cycle enforcement began October 1, 2023. A single-dose container claim that lacks both JW and JZ will reject.
No. JZ and JW are exclusive to single-dose containers as defined by FDA labeling. If the vial label reads “Multi-Dose” or “MDV,” neither modifier applies, even when the dose lands exactly on the vial size with no residual. Appending JZ to an MDV line is a denial trigger and undermines the integrity of CMS's quarterly refund data.
JZ is a HCPCS line-level modifier and does not change NDC reporting requirements. The administered line still carries the J-code, NDC, units, and JZ. Mismatches between billed units and NDC package-size math are evaluated independently of JZ; payers can deny for NDC-units mismatch even when JZ is present and correct.
Yes. JZ reporting rules are identical for biosimilars supplied in single-dose containers. The biosimilar HCPCS code (e.g., Q5118 for Byooviz, Q5125 for Fylnetra) replaces the reference J-code, but the modifier convention does not change. If no drug was discarded, append JZ on the administered line.
Medicare Part B bills in whole HCPCS units. If the administered dose plus a fractional remainder rounds to a whole-vial total with zero discarded units, the claim is JZ. If the rounded discarded amount is one unit or more, the claim is JW on a separate line. The decision is driven by the integer-unit math on the claim, not by visible residual in the vial.
No. JZ and JW are Part B medical-benefit modifiers tied to the discarded-drug refund program under Section 90004 of the Infrastructure Investment and Jobs Act. Part D pharmacy benefit claims do not use JZ. Oral oncology, self-administered injectables, and other Part D drugs follow pharmacy benefit conventions, not the JW/JZ vial-waste reporting scheme.
High. CMS and contracted auditors (RAC, SMRC, UHC's post-payment audit program) compare claim-level JZ frequency against expected waste patterns for BSA- and weight-based dosing. A practice that bills 100% JZ on Abraxane or Avastin — drugs where physiologically appropriate dosing almost never lands on a whole-vial multiple — will trigger a documentation request and potential recoupment. Reserve JZ for true no-waste scenarios; the modifier is not a coding shortcut to avoid the second claim line.
All sources are publicly available federal publications or paraphrased from trade-association educational materials. The methodology by which we resolve source disagreements is described in the Methodology.